Caxton Corp Cardiff Oncology, Inc. Transaction History

Caxton Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.11 - $7.25 $5.32 Million - $18.3 Million	-2,522,083 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.01 - $7.58 $895,537 - $1.35 Million	178,750 Added 7.63%	2,522,083 $16.8 Million
Q2 2021 Aug 16, 2021	BUY	$6.65 - $10.04 $1.52 Million - $2.29 Million	228,493 Added 10.8%	2,343,333 $15.6 Million
Q4 2020 Feb 16, 2021	BUY	$12.02 - $24.71 $3.24 Million - $6.66 Million	269,676 Added 14.62%	2,114,840 $38 Million
Q3 2020 Nov 16, 2020	BUY	$4.25 - $14.19 $1.06 Million - $3.55 Million	250,000 Added 15.67%	1,845,164 $26.2 Million
Q2 2020 Aug 14, 2020	BUY	$0.78 - $5.1 $1.15 Million - $7.55 Million	1,479,940 Added 1284.4%	1,595,164 $7.99 Million
Q2 2020 Aug 14, 2020	BUY	$0.78 - $5.1 $89,874 - $587,642	115,224 New	115,224 $577,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $112M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Caxton Corp, based on Form 13F filings with the SEC.

Stay updated on Caxton Corp with notifications on news.